Management of Anticoagulation after Intracerebral Hemorrhage

Resumption of Anticoagulation

• The American Heart Association recommends resuming oral anticoagulation at least 4-8 weeks after an intracerebral hemorrhage, provided the bleeding has stabilized and blood pressure is well-controlled 1
• In patients with a high risk of thromboembolism, resumption of anticoagulation can be considered as early as 2-3 weeks after the event, while those with a low risk may consider alternative therapy with antiplatelet agents 1, 2
• The optimal time for resuming anticoagulation is around 10 weeks after the event, when the balance between bleeding and thromboembolic risk is most favorable 1
• For patients with atrial fibrillation suffering from an intracranial bleed on oral anticoagulation, the European Heart Journal recommends initiating or resuming oral anticoagulation with an agent with low intracranial bleeding risk after 4-8 weeks 3
• High-risk patients may consider earlier restart of anticoagulation at 2-3 weeks with careful monitoring, while lower-risk patients can wait the full 4 weeks before restarting anticoagulation, based on clinical guidelines from the European Society of Cardiology and American College of Cardiology 4
• The following table outlines the recommended waiting period before restarting anticoagulation for different types of hemorrhage:

Patient-Specific Factors

• Older age is associated with a higher risk of recurrent bleeding and may influence the decision to resume anticoagulation 1
• The presence and number of microbleeds on MRI scans may also impact the risk of recurrent bleeding 1
• Limiting alcohol consumption to less than 2 drinks per day, avoiding tobacco and drug use, and treating obstructive sleep apnea if present may reduce the risk of recurrent bleeding 1
• The American Heart Association recommends targeting a blood pressure of less than 130/80 mmHg for patients with intracerebral hemorrhage, considering factors such as well-controlled hypertension, basal ganglia hemorrhage location, and lobar hemorrhage location in patient management 6, 1, 3

Alternative Therapies

• Antiplatelet monotherapy may be considered as an alternative to anticoagulation in patients with a low risk of thromboembolism 1, 2
• Percutaneous closure of the left atrial appendage may be considered in patients with atrial fibrillation 1
• Current guidelines provide level B evidence (moderate quality) for resuming antiplatelet therapy after ICH in patients with clear indications, such as recent coronary stenting or history of recurrent ischemic events, with single antiplatelet therapy preferred over dual antiplatelet therapy 6
• The European Heart Journal recommends considering factors such as bleeding occurrence, patient age, hypertension control, and basal ganglia bleed when deciding to resume antiplatelet therapy, and suggests withholding antiplatelet therapy in patients with bleeding occurred on adequately dosed NOAC, older age, uncontrolled hypertension, cortical bleed, severe intracranial hemorrhage, and multiple microbleeds 3

Imaging and Diagnosis

• The American Stroke Association recommends CT scan as the gold standard for initial evaluation of subdural hematoma, and MRI with gradient echo (GRE) and T2* susceptibility-weighted imaging is equally sensitive for acute hemorrhage and more sensitive for prior hemorrhage 7
• The following table outlines the recommended imaging modalities:

Surgical Management

• Decompressive craniectomy may be considered for patients in coma, with large hematomas and significant midline shift, or with elevated ICP refractory to medical management, according to the Stroke guideline society 10
• Craniotomy or craniectomy is preferred over burr holes for complete evacuation of the hematoma and relief of pressure in acute subdural hematomas with significant mass effect 8, 2
• Surgical evacuation via craniotomy or craniectomy is the definitive treatment for acute subdural hematoma with significant mass effect, with rapid reversal of anticoagulation if present, as recommended by the American Heart Association 2

Lifestyle Modifications and Monitoring

• Limiting alcohol consumption to less than 2 drinks per day, avoiding tobacco and illicit drug use, and treating obstructive sleep apnea if present are recommended lifestyle modifications to reduce risk 1
• Patients should be advised to seek urgent medical attention for new-onset severe headache, neurological deterioration, nausea, and vomiting, and activity restrictions for 4-6 weeks should include avoiding bending, straining, stretching, twisting, heavy lifting, and strenuous exercise, and preventing constipation 11
• Monitoring after restart is crucial, with scheduled follow-up imaging 1-2 weeks after antiplatelet resumption and monitoring for neurological symptoms suggesting recurrent bleeding 6